Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 3/20 | 0.55 |
| ▸ | FNTB | P49356 | 3/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7610150 | 1.00 | FNTA (0.55) | FNTAFNTBTDP1KMT2APGGT1B | |
| SCHEMBL6775073 | 0.92 | FNTA (0.53) | FNTAFNTBTDP1PGGT1B | |
| SCHEMBL6775080 | 0.92 | FNTA (0.53) | FNTAFNTBTDP1PGGT1B | |
| SCHEMBL6628152 | 0.84 | FNTA (0.61) | FNTAFNTBTDP1KMT2APGGT1B | |
| SCHEMBL6627994 | 0.84 | FNTA (0.63) | FNTAFNTBTDP1KMT2APGGT1B | |
| SCHEMBL6627998 | 0.84 | FNTA (0.63) | FNTAFNTBTDP1KMT2APGGT1B | |
| SCHEMBL6777004 | 0.82 | FNTA (0.55) | FNTAFNTBTDP1KMT2APGGT1B | |
| SCHEMBL6775076 | 0.81 | FNTA (0.38) | FNTAFNTBTDP1PGGT1B | |
| SCHEMBL7140058 | 0.80 | FNTA (0.56) | FNTAFNTBTDP1KMT2APGGT1B | |
| SCHEMBL6772100 | 0.80 | FNTA (0.56) | FNTAFNTBTDP1KMT2APGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693123-B2 | (4-(3-PYRIDYLAMINOMETHYLENE)-2-PHENYLBENZOYL)-N -METHYLMETHIONINE, METHYL ESTER FOR EXAMPLE; RESTENOSIS, HYPERPLASIA | UNIVERSITY OF PITTSBURGH | 2004-02-17 | — | — | US | disclosed |
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | UNIVERSITY OF PITTSBURGH (US) | 2002-12-19 | — | — | US | disclosed |
| US-6310095-B1 | INHIBITING OR TREATING CANCER, TREATING INTIMAL HYPERPLASIA ASSOCIATED WITH RESTENOSIS AND ATHEROSCLEROSIS, INHIBITING POST-TRANSLATIONAL MODIFICATION OF ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE AND/OR GERANYLGERANYLTRANSFERASE | UNIVERSITY OF PITTSBURGH | 2001-10-30 | — | — | US | disclosed |
| US-6221865-B1 | INHIBITORS OF PROTEIN FARNESYLTRANSFERASE AND PROTEIN GERANYLGERANYLTRANSFERASE. | UNIVERSITY OF PITTSBURGH | 2001-04-24 | — | — | US | disclosed |
| US-6204293-B1 | INHIBITING POST-TRANSLATIONAL MODIFICATION OF THE ONCOGENIC RAS PROTEIN BY PROTEIN FARNESYLTRANSFERASE, PROTEIN GERANYLGERANYLTRANSFERASE, OR BOTH | UNIVERSITY OF PITTSBURGH | 2001-03-20 | — | — | US | disclosed |
| WO-1998050031-A1 | INHIBITORS OF PROTEIN ISOPRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193596-A1 | Inhibitors of protein isoprenyl transferases | LANCL1, FNTB, DHCR7 | FNTA 20/4885FNTB 2/4885TDP1 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.